Senores Pharmaceuticals Q1 FY27 Earnings Call Transcript Released
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180 crore, up 36% YoY. PAT grew 56% to ₹31 crore, with EBITDA up 87% to ₹54 crore. The company forecasts FY27 revenue growth of 30-40% and PAT growth of 50-60%. Regulated markets grew 42% and emerging markets 30%.
The announcement details strong financial performance for the quarter, provides clear future growth guidance (30-40% revenue and 50-60% PAT growth for FY27), and outlines strategic expansions and acquisitions (Apnar facility, ANDA pipeline growth, PIC/S approval). These factors are material and will likely influence investor perception and stock performance.
The company reported strong year-over-year growth in revenue, EBITDA, and profit after tax. Management provided optimistic guidance for the full fiscal year and highlighted significant expansion in their ANDA portfolio and market reach. The improved EBITDA margins and cash flow positivity in emerging markets also contribute to a positive sentiment.
Senores Pharmaceuticals Limited has released the transcript of its Earnings Conference Call for Q1 FY27, held on July 27, 2026. The call, hosted by DAM Capital Advisors, featured management including Promoter and Managing Director Mr. Swapnil Shah, Chairman Mr. Sanjay Majmudar, and CFO Mr. Deval Shah.
During the call, the management highlighted a healthy performance in Q1 FY27 driven by operational excellence and a diversified business portfolio. They expressed confidence in sustaining momentum and delivering profitable growth, supported by structural growth drivers, an expanded manufacturing footprint, and strengthened R&D capabilities. The company projects revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60% for FY27, with a similar trajectory expected thereafter.
The regulated market business showed robust year-over-year revenue growth of 42%, driven by an expanding product portfolio and differentiated sales channels. The ANDA approved portfolio has nearly doubled in the past year, with 23 ANDAs commercialized and 35 planned for the next 18-20 months. The Apnar facility in Baroda, USFDA approved, is enhancing manufacturing and commercial capabilities, with production ramped up and further expansion planned.
The emerging market business grew by around 30% in Q1 FY27, with EBITDA margins improving to the mid-teens and the business becoming cash flow positive. The company is progressing towards obtaining European PIC/S approval for its Chhatral facility by Q2/Q3 FY27, which will provide access to key mid-tier markets.
Consolidated revenue from operations for Q1 FY27 stood at ₹180 crores, a 36% year-over-year increase. Consolidated EBITDA grew by 87% to ₹54 crores, with EBITDA margins at nearly 30%, improving by 810 basis points year-over-year. Profit after tax for the quarter was ₹31 crores, a 56% year-over-year increase.
Management also discussed the strategic shift in utilizing IPO proceeds from sterile injectables to expanding capacities for oral solids, citing the strong growth in the oral solid pipeline and the opportunity presented by the Apnar acquisition. The Zoraya and Amerisyn platforms are expected to commence operations around September-October 2026. Capex for FY27 is planned at ₹100-120 crores, primarily for increasing oral solid capacity and initiating an injectable pilot plant.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.